Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.17
NYSE:A's Cash-to-Debt is ranked lower than
62% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. NYSE:A: 1.17 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:A' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.63  Med: 1.3 Max: No Debt
Current: 1.17
Equity-to-Asset 0.55
NYSE:A's Equity-to-Asset is ranked lower than
59% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NYSE:A: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:A' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.71
Current: 0.55
0.31
0.71
Interest Coverage 9.68
NYSE:A's Interest Coverage is ranked lower than
68% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. NYSE:A: 9.68 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:A' s Interest Coverage Range Over the Past 10 Years
Min: 0.53  Med: 6.44 Max: 12.45
Current: 9.68
0.53
12.45
Piotroski F-Score: 8
Altman Z-Score: 4.34
Beneish M-Score: -2.51
WACC vs ROIC
11.00%
16.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 17.02
NYSE:A's Operating Margin % is ranked higher than
85% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. NYSE:A: 17.02 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:A' s Operating Margin % Range Over the Past 10 Years
Min: 1.05  Med: 11.85 Max: 16.32
Current: 17.02
1.05
16.32
Net Margin % 13.46
NYSE:A's Net Margin % is ranked higher than
88% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. NYSE:A: 13.46 )
Ranked among companies with meaningful Net Margin % only.
NYSE:A' s Net Margin % Range Over the Past 10 Years
Min: -0.69  Med: 12.28 Max: 18.85
Current: 13.46
-0.69
18.85
ROE % 13.59
NYSE:A's ROE % is ranked higher than
74% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. NYSE:A: 13.59 )
Ranked among companies with meaningful ROE % only.
NYSE:A' s ROE % Range Over the Past 10 Years
Min: -1.22  Med: 16.28 Max: 26.86
Current: 13.59
-1.22
26.86
ROA % 7.45
NYSE:A's ROA % is ranked higher than
80% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. NYSE:A: 7.45 )
Ranked among companies with meaningful ROA % only.
NYSE:A' s ROA % Range Over the Past 10 Years
Min: -0.42  Med: 7.41 Max: 11.77
Current: 7.45
-0.42
11.77
ROC (Joel Greenblatt) % 68.64
NYSE:A's ROC (Joel Greenblatt) % is ranked higher than
87% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NYSE:A: 68.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:A' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.79  Med: 44.69 Max: 84.13
Current: 68.64
7.79
84.13
3-Year Revenue Growth Rate 4.20
NYSE:A's 3-Year Revenue Growth Rate is ranked lower than
59% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. NYSE:A: 4.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:A' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 3.05 Max: 18.4
Current: 4.2
-22.9
18.4
3-Year EBITDA Growth Rate 5.40
NYSE:A's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NYSE:A: 5.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:A' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -27.7  Med: 5.8 Max: 76.6
Current: 5.4
-27.7
76.6
3-Year EPS without NRI Growth Rate 29.10
NYSE:A's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. NYSE:A: 29.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:A' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.7  Med: 11.2 Max: 135.6
Current: 29.1
-37.7
135.6
GuruFocus has detected 7 Warning Signs with Agilent Technologies Inc $NYSE:A.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:A's 30-Y Financials

Financials (Next Earnings Date: 2017-08-15)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

A Guru Trades in Q2 2016

Stanley Druckenmiller 220,300 sh (New)
Columbia Wanger 883,642 sh (New)
Joel Greenblatt 171,934 sh (+1385.65%)
Ron Baron 28,000 sh (+21.74%)
Steven Cohen 52,100 sh (+7.64%)
Pioneer Investments 107,767 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 125,000 sh (unchged)
George Soros Sold Out
Chris Davis Sold Out
PRIMECAP Management 5,018,630 sh (-2.98%)
Vanguard Health Care Fund 3,231,150 sh (-11.79%)
Mario Gabelli 172,400 sh (-14.78%)
RS Investment Management 2,149,542 sh (-19.20%)
Jim Simons 419,000 sh (-44.52%)
Paul Tudor Jones 9,330 sh (-76.25%)
Keeley Asset Management Corp 21,500 sh (-79.68%)
» More
Q3 2016

A Guru Trades in Q3 2016

Joel Greenblatt 470,942 sh (+173.91%)
Ron Baron 28,000 sh (unchged)
Stanley Druckenmiller 220,300 sh (unchged)
Pioneer Investments Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Mario Gabelli 171,800 sh (-0.35%)
Keeley Asset Management Corp 21,385 sh (-0.53%)
Paul Tudor Jones 8,991 sh (-3.63%)
PRIMECAP Management 4,681,530 sh (-6.72%)
Columbia Wanger 703,334 sh (-20.41%)
Vanguard Health Care Fund 2,540,550 sh (-21.37%)
Steven Cohen 33,600 sh (-35.51%)
Jim Simons 12,400 sh (-97.04%)
» More
Q4 2016

A Guru Trades in Q4 2016

Jim Simons 766,200 sh (+6079.03%)
Steven Cohen 370,300 sh (+1002.08%)
Paul Tudor Jones 13,571 sh (+50.94%)
Keeley Asset Management Corp 24,025 sh (+12.35%)
Ron Baron 28,000 sh (unchged)
Stanley Druckenmiller Sold Out
PRIMECAP Management 4,654,830 sh (-0.57%)
Mario Gabelli 170,400 sh (-0.81%)
Columbia Wanger 588,093 sh (-16.38%)
Vanguard Health Care Fund 1,889,350 sh (-25.63%)
Joel Greenblatt 324,174 sh (-31.16%)
» More
Q1 2017

A Guru Trades in Q1 2017

Pioneer Investments 50,326 sh (New)
Steven Cohen 996,237 sh (+169.04%)
Columbia Wanger 621,835 sh (+5.74%)
PRIMECAP Management 4,765,730 sh (+2.38%)
Vanguard Health Care Fund 1,889,350 sh (unchged)
Ron Baron 28,000 sh (unchged)
Mario Gabelli 165,000 sh (-3.17%)
Jim Simons 559,100 sh (-27.03%)
Paul Tudor Jones 9,073 sh (-33.14%)
Joel Greenblatt 67,191 sh (-79.27%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3825
Compare:NYSE:Q, NYSE:LH, NYSE:DGX, NAS:IDXX, NYSE:PKI, NYSE:BIO, NAS:DXCM, NYSE:CRL, NAS:PRAH, NAS:BRKR, NAS:EXAS, NAS:PRXL, NYSE:ALR, NAS:VWR, NAS:INCR, NAS:NEOG, NAS:MYGN, NAS:AXDX, NAS:FMI, NAS:QDEL » details
Traded in other countries:AG8.Germany,
Headquarter Location:USA
Agilent Technologies Inc is engaged in life sciences, diagnostics and applied chemical markets. The company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading health-care firm. Today, Agilent's measurement technologies serve a broad base of customers within three operating segments: life science and applied equipment (49% of sales), cross lab (which includes consumables and services at 34%), and diagnostics and genomics (17%). The United States and Europe account for 34% and 27% of revenue, respectively, with China and Japan accounting for the majority of remaining sales. Agilent is headquartered in California.

Ratios

vs
industry
vs
history
PE Ratio 33.66
A's PE Ratio is ranked higher than
55% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. A: 33.66 )
Ranked among companies with meaningful PE Ratio only.
A' s PE Ratio Range Over the Past 10 Years
Min: 3.16  Med: 16.28 Max: 48.52
Current: 33.66
3.16
48.52
Forward PE Ratio 24.81
A's Forward PE Ratio is ranked lower than
63% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. A: 24.81 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 33.66
A's PE Ratio without NRI is ranked higher than
56% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. A: 33.66 )
Ranked among companies with meaningful PE Ratio without NRI only.
A' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.2  Med: 16.41 Max: 301.43
Current: 33.66
5.2
301.43
Price-to-Owner-Earnings 36.64
A's Price-to-Owner-Earnings is ranked lower than
53% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. A: 36.64 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
A' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.1  Med: 16.18 Max: 194.42
Current: 36.64
3.1
194.42
PB Ratio 4.40
A's PB Ratio is ranked lower than
55% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. A: 4.40 )
Ranked among companies with meaningful PB Ratio only.
A' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.67 Max: 4.52
Current: 4.4
1.22
4.52
PS Ratio 4.53
A's PS Ratio is ranked lower than
57% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. A: 4.53 )
Ranked among companies with meaningful PS Ratio only.
A' s PS Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.9 Max: 7.73
Current: 4.53
0.59
7.73
Price-to-Free-Cash-Flow 30.15
A's Price-to-Free-Cash-Flow is ranked lower than
56% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. A: 30.15 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
A' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.4  Med: 15.3 Max: 68.05
Current: 30.15
5.4
68.05
Price-to-Operating-Cash-Flow 24.46
A's Price-to-Operating-Cash-Flow is ranked lower than
61% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. A: 24.46 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
A' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.31  Med: 12.51 Max: 39.2
Current: 24.46
4.31
39.2
EV-to-EBIT 25.38
A's EV-to-EBIT is ranked higher than
53% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 25.38 )
Ranked among companies with meaningful EV-to-EBIT only.
A' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 13.9 Max: 249.8
Current: 25.38
4.9
249.8
EV-to-EBITDA 19.49
A's EV-to-EBITDA is ranked higher than
51% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. A: 19.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
A' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 11.1 Max: 31.7
Current: 19.49
4
31.7
Shiller PE Ratio 30.83
A's Shiller PE Ratio is ranked higher than
71% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. A: 30.83 )
Ranked among companies with meaningful Shiller PE Ratio only.
A' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.95  Med: 20.57 Max: 46.42
Current: 30.83
9.95
46.42
Current Ratio 3.20
A's Current Ratio is ranked higher than
60% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. A: 3.20 )
Ranked among companies with meaningful Current Ratio only.
A' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.57 Max: 4.08
Current: 3.2
1.61
4.08
Quick Ratio 2.74
A's Quick Ratio is ranked higher than
57% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. A: 2.74 )
Ranked among companies with meaningful Quick Ratio only.
A' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 2.07 Max: 3.44
Current: 2.74
1.04
3.44
Days Inventory 98.27
A's Days Inventory is ranked lower than
60% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. A: 98.27 )
Ranked among companies with meaningful Days Inventory only.
A' s Days Inventory Range Over the Past 10 Years
Min: 91.25  Med: 98.82 Max: 191.04
Current: 98.27
91.25
191.04
Days Sales Outstanding 57.15
A's Days Sales Outstanding is ranked higher than
55% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. A: 57.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.45  Med: 52.14 Max: 84.27
Current: 57.15
47.45
84.27
Days Payable 47.69
A's Days Payable is ranked lower than
62% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. A: 47.69 )
Ranked among companies with meaningful Days Payable only.
A' s Days Payable Range Over the Past 10 Years
Min: 43.61  Med: 51.45 Max: 79.36
Current: 47.69
43.61
79.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.86
A's Dividend Yield % is ranked lower than
52% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. A: 0.86 )
Ranked among companies with meaningful Dividend Yield % only.
A' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 1.12 Max: 1.42
Current: 0.86
0.31
1.42
Dividend Payout Ratio 0.28
A's Dividend Payout Ratio is ranked higher than
82% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. A: 0.28 )
Ranked among companies with meaningful Dividend Payout Ratio only.
A' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.09  Med: 0.33 Max: 0.77
Current: 0.28
0.09
0.77
Forward Dividend Yield % 0.88
A's Forward Dividend Yield % is ranked lower than
58% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. A: 0.88 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.86
A's 5-Year Yield-on-Cost % is ranked lower than
68% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. A: 0.86 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
A' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.31  Med: 1.12 Max: 1.42
Current: 0.86
0.31
1.42
3-Year Average Share Buyback Ratio 0.90
A's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. A: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
A' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.5  Med: 1.05 Max: 11.4
Current: 0.9
-2.5
11.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 122.27
A's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. A: 122.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
A' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.8  Med: 11.68 Max: 1364
Current: 122.27
2.8
1364
Price-to-Tangible-Book 13.44
A's Price-to-Tangible-Book is ranked lower than
82% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. A: 13.44 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
A' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 3.89 Max: 12.49
Current: 13.44
1.1
12.49
Price-to-Intrinsic-Value-Projected-FCF 1.82
A's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. A: 1.82 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
A' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.2 Max: 2.86
Current: 1.82
0.62
2.86
Price-to-Median-PS-Value 2.38
A's Price-to-Median-PS-Value is ranked lower than
92% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. A: 2.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
A' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.93 Max: 3.9
Current: 2.38
0.38
3.9
Price-to-Graham-Number 4.48
A's Price-to-Graham-Number is ranked lower than
58% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. A: 4.48 )
Ranked among companies with meaningful Price-to-Graham-Number only.
A' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.84  Med: 2 Max: 9.54
Current: 4.48
0.84
9.54
Earnings Yield (Greenblatt) % 3.94
A's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. A: 3.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
A' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 7.2 Max: 20.2
Current: 3.94
0.4
20.2
Forward Rate of Return (Yacktman) % -4.86
A's Forward Rate of Return (Yacktman) % is ranked lower than
83% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. A: -4.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
A' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.2  Med: 8.6 Max: 78.6
Current: -4.86
-10.2
78.6

More Statistics

Revenue (TTM) (Mil) $4,324.00
EPS (TTM) $ 1.78
Beta1.56
Short Percentage of Float0.93%
52-Week Range $42.92 - 61.84
Shares Outstanding (Mil)321.34

Analyst Estimate

Oct17 Oct18 Oct19 Oct20
Revenue (Mil $) 4,400 4,625 4,819 5,068
EPS ($) 2.13 2.41 2.68 2.96
EPS without NRI ($) 2.13 2.41 2.68 2.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.03%
Dividends per Share ($) 0.53 0.63 0.66 0.66
» More Articles for NYSE:A

Headlines

Articles On GuruFocus.com
Agilent Technologies Raises Dividend 15% Dec 06 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
A High-Tech Manufacturer With Excellent Growth Prospects Nov 03 2016 
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
Agilent, Apple and Canadian Pacific Are Among Larry Robbins' New Buys Dec 22 2015 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Larry Robbins Buys Cigna, Monsanto and Sells Out McDonald's Dec 09 2015 
Agilent Technologies Drop Means Buy Now Aug 27 2015 
Why Agilent Technologies is a "Hold" Jun 17 2015 
Buy the Keysight Technologies Spinoff After the Dip Jun 17 2015 

More From Other Websites
Agilent Technologies, Inc. breached its 50 day moving average in a Bearish Manner : A-US : July 27,... Jul 27 2017
Agilent Technologies Introduces Real-Time PCR System for Clinical Diagnostics in Europe Jul 25 2017
Agilent Acquires Powerful Next Generation Sequencing IP Portfolio Jul 24 2017
New Strong Buy Stocks for July 24th Jul 24 2017
​Leadership Lesson: Short circuit negative energy - free yourself of complaints Jul 21 2017
Hans E. Bishop to Join Agilent’s Board of Directors Jul 18 2017
Agilent Technologies Presents Thought Leader Award to Dr. Ram Sasisekharan Jul 18 2017
Agilent Technologies Introduces New High-Sensitivity NGS Target Enrichment Solution Jul 17 2017
Top Ranked Momentum Stocks to Buy for July 17th Jul 17 2017
Agilent Technologies Presents Early Career Professor Award to Dr. Gary Patti Jul 10 2017
Agilent Boosts Raman Spectroscopy With Cobalt Light Systems Jul 10 2017
There's More Than Meets the Eye to Danaher Corporation Jul 07 2017
Agilent Technologies Acquires Raman Spectroscopy Innovator, Cobalt Light Systems Jul 07 2017
Why Investors Should Buy Agilent Technologies (A) Right Now Jul 05 2017
Edited Transcript of A earnings conference call or presentation 22-May-17 8:30pm GMT Jul 01 2017
ETFs with exposure to Agilent Technologies, Inc. : June 28, 2017 Jun 28 2017
Shipping Magnate Bets On Oil's Recovery---Energy Journal Jun 27 2017
Why Agilent Technologies (A) Stock Might be a Great Pick Jun 23 2017
Agilent (A) Expands Use of Cancer Diagnostics in Europe Jun 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}